XSHE
300132
Market cap451mUSD
Oct 09, Last price
6.23CNY
1D
2.81%
1Q
9.30%
Jan 2017
-40.53%
IPO
-36.09%
Name
Fujian Green Pine Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Fujian Green Pine Co., Ltd. focuses on the entire lifecycle of turpentine derivatives, from initial research and development through to manufacturing and sales. Their extensive product line encompasses a wide array of chemical compounds, such as synthetic camphor, isobornyl acetate, camphene, borneol flakes, para cymene, pinene, dipentene, isoborneol, both crystalline and anhydrous sodium acetate, isobornyl (meth) acrylate, myrcene, benzyl acetate, QS keton, and various solvent oils. These products find diverse applications across sectors including flavorings, fragrances, pharmaceuticals, personal care items, cleaning solutions, and paints and coatings. The company maintains a global presence, conducting business across Asia, Europe, North America, South America, Oceania, and Africa. Established in 1958, the firm is headquartered in Jianyang, China, and adopted its current name, Fujian Green Pine Co., Ltd., in May 2009, having previously been known as Jianyang City Green Pine Chemical Co., Ltd.
Key people
Yucong Wang
Chief Financial Officer · since 2018
Ruzheng Ouyang
Executive Vice President · since 2023
Qihui Luo
Vice President, Secretary of the Board · since 2022
Zhanhua Fan
Chairman of the Board, President · since 2022
Shida Lin
Director · since 2020
Yuecong Lin
Vice President, Director · since 2021
Independent Director · since 2018
Hao Huang
Independent Director · since 2024
Xiaoming Qian
Independent Director · since 2022
Qingquan Tang
Independent Director · since 2022
Headquarters & legal address
福建省南平市建阳区回瑶工业园区
南平市, FJ 352400
CN
南平市, FJ 352400
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||